TETRAPHASE PHARMACEUTICALS INC — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/757cac26-e614-4cdf-a0f6-ab8b48095757/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2019 | $7.4M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-010220 |
| FY 2018 | $18.9M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-008034 |
| FY 2017 | $9.7M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-008034 |
| FY 2016 | $5.1M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-004141 |
| FY 2015 | $11.7M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-013419 |
| FY 2014 | $9.1M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-081060 |
| FY 2013 | $20.7M | 2006-07-08 – 2014-03-31 | evidence 0001193125-14-193706 |
| FY 2012 | $10.5M | 2006-07-08 – 2013-03-31 | evidence 0001193125-13-216677 |
| FY 2011 | $185.0k | 2011-01-01 – 2011-12-31 | evidence 0001193125-14-086844 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
TETRAPHASE PHARMACEUTICALS INC — all facts · Net Income · Operating Income